Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Filings indexed 859 across all filing types
Latest filing 2017-12-14 Regulatory Filings
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC. It registers securities to be issued under inducement equity awards to employees. The document includes details about the securities, registration fees, incorporation by reference of other filings, indemnification provisions, and exhibits such as share option agreements and legal opinions. It is a regulatory filing related to securities registration and employee equity awards, not a financial report, earnings release, or management discussion. The document is lengthy (15,000 characters) and contains the full registration statement text, not just an announcement or certification. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers miscellaneous SEC filings that do not fit other specific categories.
2017-12-14 English
Regulatory Filings 2017
Regulatory Filings
2017-12-04 English
SC 13G
Major Shareholding Notification
2017-11-03 English
10-Q
Interim / Quarterly Report Q3 2017
2017-11-01 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 27, 2017. It reports the closing of a public offering by the company uniQure N.V. The text includes a press release about the closing of the public offering as Exhibit 99.1. There are no financial statements or detailed financial data included in the text, only an announcement of the event and the filing of the press release. The document length is 3178 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, announcements about fundraising or financing activities such as public offerings fall under Capital/Financing Update (CAP). Therefore, the appropriate classification is CAP with high confidence.
2017-10-27 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 24, 2017. It reports the entry into a material definitive agreement, specifically an underwriting agreement for a public offering of shares. The document details the terms of the offering, including the number of shares, price, net proceeds, and the underwriters involved. It also references a press release about the pricing of the public offering. There are no financial statements or comprehensive financial data presented, nor is this a report of earnings or management discussion. The content focuses on a capital raising event through a public offering, which fits the category of Capital/Financing Update. The document length is 5588 characters, which is sufficient to contain substantive information about the financing event rather than just an announcement of a report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2017-10-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.